Tag Archive for: Cancer

STORM Therapeutics announces closing of USD $30M Series B financing

/in

Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias  Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification 14 December 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying […]

Read more

Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards

/in

AMSTERDAM, THE NETHERLANDS, December 13, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at […]

Read more

CellCentric presents early clinical data at ASH

/in

Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Inobrodib is an oral drug showing good long-term tolerability at the recommended phase 2 dose as monotherapy Objective responses have been observed in heavily pre-treated relapsed/ refractory multiple myeloma patients Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear […]

Read more

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

/in

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC). Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron. Top line interim results anticipated in third quarter of 2023. Oegstgeest, 30 November […]

Read more

Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards

/in

AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at […]

Read more
© Optimum Strategic Communications.